Cargando…
Recent insights into the use of immune checkpoint inhibitors in gastric cancer
Gastric cancer (GC) is the fifth most incident and the fourth deadliest cancer worldwide. GC is a heterogeneous disease from the histological and molecular standpoints. This malignancy is mostly diagnosed at advanced stages of the disease, where the available therapeutic interventions are not effect...
Autores principales: | Rodrigues, Soraia, Figueiredo, Ceu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824404/ https://www.ncbi.nlm.nih.gov/pubmed/35146175 http://dx.doi.org/10.1097/j.pbj.0000000000000162 |
Ejemplares similares
-
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022) -
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018) -
Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018) -
Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023) -
Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress
por: Song, Xiaoxu, et al.
Publicado: (2020)